Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis

Abstract

OBJECTIVE: We compared 220 µg daily intranasal aqueous triamcinolone acetonide (TAA AQ) with 200 µg daily fluticasone propionate (FP) for relief of seasonal allergic rhinitis symptoms. STUDY DESIGN AND SETTING: Randomized, parallel-group, investigator-blind study included patients with symptomatic seasonal allergic rhinitis. After a baseline period, TAA AQ or FP was taken for about 21 days. Nasal symptom (discharge, stuffiness, itching, sneezing) severity was recorded twice daily; total nasal symptom score was calculated. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire. RESULTS: Reductions in individual symptoms and total nasal symptom score were statistically significant versus baseline and were equivalent between treatments: −3.15 ± 0.19 with TAA AQ (n = 148) and ∼3.17 ± 0.18 with FP (n = 147) (95% confidence interval for the difference, −0.7391 to 0.3693). Clinically and statistically significant improvements in Rhinoconjunctivitis Quality of Life Questionnaire scores were comparable. CONCLUSION: TAA AQ and FP were equally efficacious in relieving seasonal allergic rhinitis symptoms and improving health-related quality of life. SIGNIFICANCE: Differences in molecular potency of intranasal steroids do not confer differences in efficacy.

Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis

“…No statistically significant differences between the 2 active treatment groups were noted. Triamcinolone acetonide and fluticasone propionate, both once‐daily, were compared over a 3‐week treatment period in SAR patients 60 . In the ocular outcome variable that was assessed in this study (the eye symptom domain of RQLQ), triamcinolone acetonide and fluticasone propionate were both superior to placebo and were not significantly different from each other.…”

Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study

“…The intranasal administration of TAA or FP significantly improved miniRQLQ scores, both overall and in the 5 individual domains, over 4 weeks in patients with PAR in Russia. Other studies have demonstrated improvements in QoL in patients with seasonal or persistent AR who received TAA [7,11,12]. Our analysis has been broadened to study the effects of TAA in patients with PAR.…”

“…Many different properties of each intranasal corticosteroid have a direct or indirect correlation that will determine their safety and efficacy, such as volume of distribution, tissue deposition, receptor binding targeting, tissue retention, lipophilicity, glucocorticoid potency, systemic potency, and elimination half-life [14,23,24]. Comparative studies that have evaluated TAA and FP demonstrated a similar safety profile of these intranasal corticosteroids despite the difference in bioavailability [9,11,12]; therefore, TAA can be considered a well-tolerated choice.…”

Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis

“…Six studies had insufficient outcome data for quantitative synthesis (Ratner et al, 1992;van Bavel et al, 1994;Bronsky et al, 1996;Gross et al, 2002;Lumry et al, 2003;Meltzer et al, 2004). Therefore, only 26 studies, 13 with 5,134 SAR patients (Meltzer et al, 1998;Berger et al, 2003;Gawchik et al, 2003;Ratner et al, 2006;Fokkens et al, 2007;Kaiser et al, 2007;Andrews et al, 2009;Jacobs et al, 2009;Okubo et al, 2009;Prenner et al, 2010;Meltzer et al, 2011;Igarashi et al, 2012;Ratner et al, 2015) and 13 with 4,393 PAR patients (Kobayashi et al, 1995;Fokkens et al, 2002;Tai and Wang, 2003;Chervinsky et al, 2007;Meltzer et al, 2007;Rosenblut et al, 2007;Nathan et al, 2008;Vasar et al, 2008;Weinstein et al, 2009;Baena-Cagnani and Patel, 2010;Given et al, 2010;Meltzer et al, 2010;Karaulov et al, 2019), were included in NMA. Of 26 studies, 3 (Fokkens et al, 2002;Weinstein et al, 2009;Baena-Cagnani and Patel, 2010) were conducted in children and 23 in adults and adolescents.…”

“…Of 26 studies, 3 (Fokkens et al, 2002;Weinstein et al, 2009;Baena-Cagnani and Patel, 2010) were conducted in children and 23 in adults and adolescents. Three studies (Berger et al, 2003;Tai and Wang, 2003;Karaulov et al, 2019) compared active drug VS active drug, 1 (Okubo et al, 2009) compared 2 active drugs VS placebo, and 22 compared active drug VS placebo.…”